• Celerion Newsletter
Belfast - Center of Excellence for Respiratory

Celerion

committed to service excellence

Primary Navigation for Celerion

  • Home
  • About Celerion
    • Why Celerion?
    • Mission, Vision and Credo
    • Management Team
    • Who We Work With
    • Locations
    • Environmental Sustainability
  • Applied Translational Medicine
    • Key Elements of Success
  • Services
    • Global Clinical Research
      • AAHRPP Accreditation
      • Phase I and lla Studies
      • In-hospital Beds
      • Study Experience
      • Belfast – Center of Excellence for Respiratory
      • Early Cardiac Services
      • Hybrid Phase I/ECG Core Lab
      • ADME/Mass Balance
      • Microtracer Studies
      • USP <797> Clean Room
      • ClinQuick® Electronic Data Acquisition
      • Recruitment
    • Clinical Pharmacology Sciences
      • Modeling and Simulation
      • Study Design and Protocol Development
      • Data Programming
      • Biostatistics
      • Pharmacokinetics/Pharmacodynamics (PK/PD)
      • Medical Writing and Reporting
      • Streamlined Data Flow Process
    • Global Bioanalytical Services
      • Small Molecule
      • Large Molecule
      • Electronic Laboratory Notebook System
      • ADME/Mass Balance
    • Drug Development Services
      • Biopharmaceutical Development
      • Program and Project Management
      • Regulatory Affairs
  • Celerion Europe
    • Global Clinical Research
    • Clinical Pharmacology Sciences
    • Global Bioanalytical Services
    • Management Team
  • The Biosimilars Alliance
    • The Biosimilars Alliance – Overview
    • The Biosimilars Alliance – Benefits
  • Case Studies
    • Global Clinical Research
      • Responding to an Unexpectedly High Drop Rate
      • Mass Balance Study
      • Semen Clinical Trials
    • Clinical Pharmacology Sciences
      • Partnering with Biotechnology Companies
      • Partnering with Large Pharmaceutical Companies
      • Protocol Study Design and Development for Generic Studies
      • Difficult to Recruit Population
      • Consistent Database Structure for Programs of Studies
    • Global Bioanalytical Services
      • Improved Desmopressin Analysis of Clinical Samples
      • Optimized LC-MS/MS Method for New Observed Metabolite
      • Bioanalytical Support of Oncology Studies
      • High Throughput Bioanalytical Analysis
      • Partnering with Biotechnology Companies
      • Partnering with Pharmaceutical Companies
      • Development of an LC-MS/MS Peptide Method
    • Drug Development Services
      • Support of CMC to IND for Novel First-in-Class Small Molecule Drugs
      • Rapid Proof-of-Concept for Novel Drug Treatment for Rare Metabolic Disease
      • Proof-of-Concept Efficacy Clinical Study
      • European Biotechnology Company Seeking First-in-Human U.S. Clinical Study
      • Asian Biotechnology Company with CNS Compound
  • White Papers
  • Other Resources
  • News & Events
    • Press Room
    • Conferences
    • Symposia
    • Webinars
  • Participate in a Study
  • Careers
    • Message from the CEO
    • Culture
  • Spring 2013 Newsletter
  • Fall 2012 Newsletter
  • Spring 2012 Newsletter

Celerion Europe

Global Clinical Research

Partnering with Celerion means working with one of the most experienced CROs in the world.

Celerion’s facility in Belfast, Northern Ireland UK, has over 20 years experience with 78 beds across 4 flexible wards. The tenure of the staff in Belfast is the lynchpin of its success having executed well over 600 studies to date.

The Belfast facility has an unbeatable record in Europe for study participant recruitment, both in healthy and patient populations. The dedicated recruitment and call centre staff are renowned in the industry for starting studies full and on-time. Access to special populations via Celerion’s proprietary database of special populations (includes elderly subjects, hypo-gonadism , male erectile dysfunction) is enhanced by relationships with a broad network of primary care physicians.

Celerion’s facility in Belfast is a global leader in respiratory studies. The recent membership within the UK’s Translational Research Partnership in Respiratory will enable Celerion to work with key decision makers and thought leaders in the UK to develop and execute Phase I and IIa studies with targeted patient populations. Clients benefit from faster access to data that expedites decision making and speeds up the path to clinical Proof-of-Concept.

Accreditations

  • MHRA Standard & Supplementary accreditation is to assure the highest level of volunteer care.
  • ANVISA accreditation and successful audits from the FDA ensures studies are run with the highest attention to detail by our experienced study team.
  • College of American Pathologists (CAP) accredited on-site Clinical Laboratory ensures results are available when required.
  • French Tax accreditation (financial assistance for companies with an office situated in France)
  • GMP-licensed facility with dedicated pharmacist and Qualified Person (QP) on staff. Pharmacy capable of preparing a range of pharmaceutical dosage forms including sterile products and licensed to handle Schedule II, III, IV & V drugs.

Phase I and IIa experience includes:

  • Equivalence studies including Biosimilars, oral contraceptives and high dose opiate analgesic studies.
  • Obesity studies including long confinement in excess of 40 days in-house
  • Respiratory studies including mild to moderate & severe asthmatics, COPD and Cystic Fibrosis. A recognized member of the UK’s Translational Research Partnership in Respiratory.
  • Androgenic agent and erectile dysfunction studies (including specialized techniques such as penile plethysmography).
  • Specialist techniques for “andropause” and associated osteopenia/sarcopenia (DEXA scans, muscle biopsies, etc.)
  • Cognitive function assessments
  • Ophthalmological specialist procedures (Optical coherence tomography)
  • Gastro-intestinal – including gastric pH monitoring

See also…

Press Release: Celerion Builds on Respiratory Capabilities With the Addition of an On-site Bronchoscopy Suite

Press Release: Celerion receives license enabling Investigational Medicinal Products (IMPs) to be imported directly to their GMP-licensed facility

Press Release: Celerion recognized as member of the UK Respiratory Therapeutic Capability Cluster

Webinar: Value of Early Safety Assessments

For more information contact us

Footer Naviation

  • About
  • Locations
  • Careers
  • Request a Proposal
  • Contact
  • Privacy Policy
© 2013 Celerion